JDD Buzz Series | Melasma in Men
Tranexamic acid is one of the latest therapies for treating melasma, and one that’s most commonly prescribed for women. An editorial published in the April issue of the Journal of Drugs in Dermatology encourages dermatology clinicians to also consider the effect melasma has on men and to utilize tranexamic acid as a treatment option.
I interviewed the authors, dermatologist and Mohs surgeon A …
Tranexamic acid is one of the latest therapies for treating melasma, and one that’s most commonly prescribed for women. An editorial published in the April issue of the Journal of Drugs in Dermatology encourages dermatology clinicians to also consider the effect melasma has on men and to utilize tranexamic acid as a treatment option.
I interviewed the authors, dermatologist and Mohs surgeon A … 
Topical minoxidil and, more recently, low-dose oral minoxidil are often used to treat hair disorders. But are these treatments safe and effective for scarring alopecia? A scoping review published in the March issue of the Journal of Drugs in Dermatology sought to determine what research says about the use of these treatments for central centrifugal cicatricial alopecia, frontal fibrosing alopecia, … 
Dermatology residents want training in caring for sensitive skin, yet they aren’t receiving it, according to a study published in the February issue of the Journal of Drugs in Dermatology. The authors assert that this points to a gap in residency education as well as a lack of consensus about sensitive skin within dermatology.
To find out more about residency education on sensitive skin, I in … 
Do implicit bias and race-compliance stereotyping impact clinical decision making in psoriasis? A feasibility study published in the February issue of the Journal of Drugs in Dermatology sought to answer this question.
To learn more about the key findings and takeaways, I interviewed one of the authors, Rithu Srikantha, MD, associate professor of dermatology at the Feinberg School of Medicine/N … 
Media attention about oral minoxidil has impacted access to the hair loss drug in the Washington, D.C. area, according to a study published in the January issue of the Journal of Drugs in Dermatology. Researchers found shortages of the drug in D.C.-area pharmacies more than a year after an article about the treatment appeared in The New York Times.
To find out more about oral minoxidil access, … 